Summit Therapeutics (SMMT) Free Cash Flow: 2016-2025
Historic Free Cash Flow for Summit Therapeutics (SMMT) over the last 8 years, with Sep 2025 value amounting to -$93.2 million.
- Summit Therapeutics' Free Cash Flow fell 206.87% to -$93.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$270.2 million, marking a year-over-year decrease of 139.05%. This contributed to the annual value of -$142.2 million for FY2024, which is 85.00% down from last year.
- According to the latest figures from Q3 2025, Summit Therapeutics' Free Cash Flow is -$93.2 million, which was down 39.56% from -$66.7 million recorded in Q2 2025.
- In the past 5 years, Summit Therapeutics' Free Cash Flow registered a high of $5.2 million during Q4 2022, and its lowest value of -$93.2 million during Q3 2025.
- Its 3-year average for Free Cash Flow is -$40.1 million, with a median of -$30.4 million in 2024.
- As far as peak fluctuations go, Summit Therapeutics' Free Cash Flow skyrocketed by 155.93% in 2022, and later crashed by 474.18% in 2023.
- Over the past 5 years, Summit Therapeutics' Free Cash Flow (Quarterly) stood at -$9.3 million in 2021, then spiked by 155.93% to $5.2 million in 2022, then tumbled by 474.18% to -$19.5 million in 2023, then slumped by 150.18% to -$48.7 million in 2024, then plummeted by 206.87% to -$93.2 million in 2025.
- Its Free Cash Flow stands at -$93.2 million for Q3 2025, versus -$66.7 million for Q2 2025 and -$61.6 million for Q1 2025.